Clinical trial
A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and…
NCT00192608 · Kirby Institute, Other · Completed
Key facts
| NCT number | NCT00192608 |
|---|---|
| Title | A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study |
| Official title | A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation. |
| Acronym | ASK-500 |
| Lead sponsor | Kirby Institute, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | saquinavir 500 formulation, cross-over arm |
| Enrollment | 40 |
| Start date | Nov 1, 2004 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Jun 26, 2009 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: